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Abstract 26 
Significant improvements in survival for children with acute myeloid leukaemia (AML) have 27 
been made over the past three decades, with overall survival rates now approximately 60-28 
70%. However, these gains can be largely attributed to more intensive use of conventional 29 
cytotoxics made possible by advances in supportive care, and although over 90% of children 30 
achieve remission with frontline therapy, approximately one third in current protocols 31 
relapse. Furthermore, late effects of therapy cause significant morbidity for many survivors. 32 
Novel therapies are therefore desperately needed. Early phase paediatric trials of several new 33 
agents such as clofarabine, sorafenib and gemtuzumab ozogamicin have shown encouraging 34 
results in recent years. Due to the relatively low incidence of AML in childhood, the success 35 
of paediatric early-phase clinical trials is largely dependent upon collaborative clinical trial 36 
design by international cooperative study groups. Successfully incorporating novel therapies 37 
into frontline therapy remains a challenge, but the potential for significant improvement in 38 
the duration and quality of survival for children with AML is high. 39 
 40 
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Introduction 45 
Acute myeloid leukemia (AML) is a heterogeneous class of leukaemias with an age-related 46 
incidence.1 AML is relatively rare in children, accounting for 15-20% of paediatric 47 
leukaemias, but causes a disproportionate number of childhood cancer deaths. For children 48 
less than 15 years of age overall survival (OS) rates are now approximately 60-70%.2-5 49 
Although there has been a steady and gradual improvement in survival for younger adults, it 50 
is clear that progress has plateaued for children, with survival rates being substantially 51 
inferior to those being achieved for acute lymphoblastic leukaemia (ALL), where OS exceeds 52 
80%.4,6 53 
 54 
Conventional AML therapy is essentially the same for adults and children and based on 55 
intensive use of cytarabine or other nucleoside analogs and anthracyclines. Etoposide is 56 
frequently used in paediatric induction regimens, although there is no good evidence it is of 57 
benefit in adult studies and when combined with cytarabine and daunorubicin in children, 58 
etoposide provided no advantage compared to thioguanine with cytarabine and 59 
daunorubicin.2,7 Although chemotherapy will induce complete remission (CR) in 60 
approximately 90% of children, approximately one third relapse.4,5 Relapsed AML is 61 
associated with high morbidity and mortality, with allogeneic haematopoietic stem cell 62 
transplantation (HSCT) generally regarded as the most effective anti-leukaemic therapy 63 
available.6 Most re-induction regimens, at least in children, involve high-dose cytarabine in 64 
combination with other agents such as anthracyclines. Addition of liposomal daunorubicin to 65 
the commonly utilized FLAG regimen (fludarabine, high-dose cytarabine and G-CSF) has 66 
been shown to improve the early response rates to chemotherapy from 58% to 68% (P = 67 
0.047).8 Not surprisingly, the likelihood of achieving a second CR decreases dramatically 68 
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with each failed therapeutic attempt, with only one third of children with relapsed AML 69 
becoming long-term survivors.8,9 70 
 71 
Although the past 30 years has seen major improvements in overall survival for childhood 72 
AML, additional gains are unlikely to be achieved by simply intensifying conventional 73 
cytotoxic chemotherapy further.6 Chemotherapy such as etoposide and anthracyclines is 74 
limited not only by acute toxicity, but also late effects such as increased risks of secondary 75 
malignancy and cardiotoxicity.10,11 Such late effects are of particular concern in paediatrics 76 
since treatment occurs during periods of growth and development, and the duration of 77 
survivorship is much greater than adults. Less toxic and more effective therapies for AML in 78 
children, and adults, are therefore urgently needed. The ever-expanding array of molecular 79 
abnormalities associated with AML promises to further refine current risk-stratified treatment 80 
and facilitate individualised therapy with novel therapeutics specifically targeting these 81 
leukaemogenic abnormalities.5 Such an approach should improve outcomes for those children 82 
who have historically done poorly and, potentially, permit de-intensification of therapy for 83 
those children with low-risk disease, as has been achieved with paediatric ALL. 84 
 85 
Several early-phase clinical trials of novel therapies have been completed over the past 86 
decade and an encouraging number of studies are in progress (Table I). A major limitation for 87 
progress in childhood AML, however, is that paediatric studies with novel agents usually 88 
don’t commence until preliminary toxicity and efficacy profiles have been established in 89 
adults. Whilst this may be justifiable from a patient-safety perspective, it slows the process of 90 
paediatric drug development. Furthermore, it is increasingly recognized that AML biology is 91 
at least partially different in children compared to adults, so extrapolating anticipated efficacy 92 
from adult studies to children can be challenging. For example, ‘epigenetic’ mutations of 93 
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DNMT3A, IDH1/2, TET2 and NPM1 all occur much less frequently in children than in 94 
adults.12-16 95 
Novel classes of therapeutics investigated in childhood AML in recent years include purine 96 
nucleoside analogs, small molecule kinase inhibitors and immunomodulatory therapies. Here 97 
we review the results of these trials and highlight some of the more promising agents 98 
emerging from adult trials. 99 
 100 
Novel purine nucleoside analogs 101 
The cytidine analog and DNA polymerase inhibitor cytarabine forms the backbone of 102 
conventional AML therapy in both children and adults. It is not surprising that novel 103 
cytarabine derivatives have delivered some promising results. Cladribine and fludarabine 104 
were the first two such derivatives developed. Unlike cytarabine, they inhibit both DNA 105 
polymerase and ribonucleotide reductase, thereby depleting deoxynucleotide pools.17 106 
Cladribine has shown encouraging results in combination with cytarabine18, topotecan19 and 107 
idarubicin.20 Interestingly, the FAB M5 subtype of AML appears more responsive to 108 
cladribine than other morphological subtypes.21 Fludarabine, in combination with cytarabine 109 
± an anthracycline, has become a widely used re-induction regimen for children with relapsed 110 
AML.8,9,22,23 The dose-limiting neurotoxicity of cladribine and fludarabine however, 111 
prompted the development of clofarabine. After efficacy was demonstrated for 112 
relapsed/refractory ALL, in December 2004 clofarabine became the first anti-leukaemic drug 113 
approved for use in childhood prior to adult use approval.17 The efficacy and potential role of 114 
clofarabine in paediatric AML is discussed in detail below. 115 
 116 
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Clofarabine 117 
Clofarabine is a structural hybrid of cladribine and fludarabine, designed to have improve 118 
efficacy, through reduced deamination by adenosine deaminase and improved stability, whilst 119 
avoiding the formation of toxic metabolites such as 2-F adenine caused by glycosidic bond 120 
cleavage of fludarabine.17 Clofarabine is converted intracellularly to clofarabine 121 
monophosphate by deoxycytidine kinase (dCK), then to clofarabine triphosphate by 122 
additional kinases. The triphosphate form of clofarabine impairs DNA synthesis and repair 123 
via inhibition of both ribonucleotide reductase and DNA polymerase and induces apoptosis 124 
via mitochondrial pathways.24 As a potent ribonucleotide reductase inhibitor, clofarabine 125 
increases dCK activity, thus potentiating its own activation and theoretically that of other 126 
drugs such as cytarabine.24 The maximum tolerated dose (MTD) as a single-agent is 52 127 
mg/m2/day for 5 days in children and 40mg/m2/day for 5 days in adults with hematologic 128 
malignancies, with reversible hepatotoxicity and skin rash being the main non-129 
haematological dose limiting toxicities (DLTs).25 Although the liver and skin toxicities are 130 
reversible when clofarabine is given as a single agent, it should be noted that a potential 131 
interaction with intrathecal methotrexate exists, with at least one case report describing fatal 132 
skin and hepatoxicity in a child with a CNS-relapse of pre-B ALL given clofarabine 52 133 
mg/m2/day for 5 days, together with triple intrathecal therapy (hydrocortisone, methotrexate 134 
and cytarabine).26 135 
 136 
A phase II study of clofarabine as a single agent in children with relapsed/refractory AML 137 
had an overall response rate (ORR) of 26%, comprising one CR with incomplete platelet 138 
recovery (CRp) and 10 partial responses (PR).25 Although most responses were partial, the 139 
trial population was heavily pretreated, with patients having received a median of two prior 140 
treatment regimens (range one to five). Furthermore, six of 28 (21%) patients refractory to 141 
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prior therapy responded and approximately one third of clofarabine treated patients 142 
proceeded to HSCT.25 Subsequent interpretation of the HSCT data is problematic however, 143 
considering that most patients went to HSCT in PR, rather than CR. The toxicity profile was 144 
reported as being expected for the patient population, with frequent (≥ 15%) grade 3 adverse 145 
events being febrile neutropaenia, catheter-related infection, epistaxis, hypotension, nausea, 146 
fever, elevated transaminases and hypokalaemia.25 147 
 148 
Clofarabine has also been trialed in combination with conventional and targeted therapeutic 149 
agents. In a phase I study of the multi-kinase/FLT3 inhibitor sorafenib in combination with 150 
clofarabine and cytarabine, responses were seen in both FLT3-wild type (-WT) and FLT3-151 
ITD+ patients.27 This trial is discussed further below. A phase I trial of clofarabine in 152 
combination with etoposide and cyclophosphamide for children with relapsed and refractory 153 
acute leukemias resulted in an ORR of 55% (9/20 CR + 2/20 CRp) for ALL patients and 154 
100% (1/5 CR + 4/5 CRp) for AML patients.28 When given for five consecutive days during 155 
induction and four consecutive days in consolidation for up to eight cycles (median time 156 
between cycles 34 days), the recommended phase II doses (RP2D) of clofarabine, 157 
cyclophosphamide and etoposide were 40, 440 and 100 mg/m2 respectively. The toxicity 158 
profile was similar to that seen in the monotherapy phase II study of clofarabine.28 159 
 160 
A phase I study of clofarabine in combination with liposomal daunorubicin for children with 161 
relapsed/refractory AML was recently completed. Patients received clofarabine on days 1-5 162 
(30 mg/m2, escalated to 40 mg/m2), and liposomal daunorubicin (60 mg/m2) days 1, 3 and 5. 163 
Nine patients were enrolled, with the most common severe adverse event being febrile 164 
neutropaenia, but no DLTs observed. One third of patients achieved CR and proceeded to 165 
HSCT. The 40 mg/m2 clofarabine cohort is being extended to accrue more efficacy data.29 166 
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 167 
There is intense ongoing interest in clofarabine for AML in adults and children, with no 168 
fewer than 35 open studies of the drug in AML currently registered on ClinicalTrials.gov. A 169 
major challenge, however, remains in defining how best to use clofarabine in both upfront 170 
and second-line AML treatment regimens. Results of randomised studies in adults are 171 
expected in the near future, including the NCRI AML16 trial for adults over 60 years of age, 172 
which randomised newly-diagnosed patients to induction with either daunorubicin and 173 
cytarabine or daunorubicin and clofarabine (ISRCTN 11036523). The current NCRI AML17 174 
trial for younger adults with AML is randomising poor risk patients (defined by a 175 
statistically-derived risk score based on presenting disease characteristics and remission 176 
status after course I chemotherapy), to either daunorubicin plus clofarabine or FLAG-Ida 177 
prior to HSCT (ISRCTN55675535). For childhood AML, a randomised phase II study 178 
sponsored by St Jude Children’s Research Hospital (SJCRH) is ongoing, comparing end-of-179 
induction MRD for children treated with clofarabine and cytarabine to conventional ADE 180 
therapy (cytarabine, daunorubicin, etoposide; NCT00703820).  181 
 182 
FLT3 inhibition 183 
Internal tandem duplication (ITD) or tyrosine kinase domain (TKD) mutations of the fms-like 184 
tyrosine kinase 3 (FLT3) gene occur frequently in AML, resulting in constitutive FLT3 185 
signaling and stimulation of leukaemic proliferation.30 The incidence of FLT3-ITD in AML 186 
increases with age, occurring in approximately 23% of adults and 12% of children overall 187 
with de novo AML, whilst the incidence of FLT3-TKD is relatively constant across all age 188 
groups at approximately 7%.31,32 Although FLT3-TKD mutations do not appear to impact on 189 
prognosis, the presence of FLT3-ITD has consistently been associated with inferior outcome, 190 
principally as a result of increased relapse rate.33 High FLT3-ITD/FLT3-WT allelic ratios 191 
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(AR) carry a particularly poor prognosis, with survival rates of less than 20% in both adults 192 
and children.31,34,35 Furthermore, ex vivo studies have demonstrated increased dependence of 193 
high AR FLT3-ITD+ AML blasts to FLT3 signaling, consistent with the concept of 194 
“oncogene addiction”.36 The identification of secondary FLT3-TKD mutations in patients 195 
treated with FLT3 inhibitors is also evidence of clonal selection and cellular dependency on 196 
constitutive FLT3 signaling.37-39 197 
 198 
Small molecule inhibition of FLT3 kinase has therefore been vigorously pursued as a 199 
therapeutic strategy over the past decade and detailed critiques of each individual FLT3 200 
inhibitor developed to date have recently been published.33,40 Initial “first generation” FLT3 201 
inhibitors, such as CEP-701 (lestaurtinib) and PKC412 (midostaurin), were non-selective 202 
compounds already in early clinical development and subsequently identified as having 203 
potent anti-FLT3 activity. These compounds have undergone extensive preclinical and 204 
clinical evaluation with major phase III trials ongoing. So-called “second-generation” FLT3 205 
inhibitors such as AC220 (quizartinib), designed with increased potency and selectivity for 206 
FLT3, are currently being evaluated in early-phase clinical trials. 207 
 208 
Preclinical studies have demonstrated that sustained inhibition of FLT3 phosphorylation to 209 
less than 15% of baseline is required to achieve cytotoxicity.41,42 Furthermore, several 210 
pharmacokinetic (PK) and pharmacodynamic (PD) studies from clinical trials have 211 
consistently confirmed that clinical responses are unlikely in patients who do not achieve 212 
adequate FLT3 inhibition.41-45 213 
 214 
Finally, although newer more potent and selective FLT3 inhibitors such as AC220 are 215 
showing encouraging results in single-agent trials, it appears that FLT3 inhibitors are likely to 216 
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be of most benefit when used in combination with conventional chemotherapy.33 It is worth 217 
noting that myelosuppression from conventional chemotherapy itself has been shown to 218 
increase the production of FLT3 ligand (FL) which can decrease the efficacy of a number of 219 
FLT3 inhibitors, at least in vitro.46 These observations highlight the need for effective PD 220 
biomarker assays to monitor how effectively FLT3 is being targeted. Assays such as the 221 
plasma inhibitory activity (PIA) assay have been used to demonstrate that effective FLT3 222 
inhibition can still be achieved clinically however, despite elevations in FL (discussed in 223 
more detail below).47  224 
 225 
Sorafenib 226 
The multi-kinase inhibitor, sorafenib, has potent activity against FLT3 and increased activity 227 
against FLT3-ITD+ AML cells compared to FLT3-WT cells.48 Although sorafenib was 228 
assessed by the Pediatric Preclinical Testing Program (PTPP), only one AML cell line was 229 
tested.49 In the PTPP screen, the FLT3-WT cell line Kasumi-1 had an in vitro IC50 of 0.02 230 
M.49 Pre-clinical studies of sorafenib and another multi-kinase inhibitor, sunitinib, at 231 
SJCRH examined a broader panel of AML cell lines and demonstrated similar in vitro 232 
sensitivity of Kasumi-1 (sorafenib IC50 0.04 M), but markedly increased sensitivity of the 233 
FLT3-ITD+ paediatric cell line MV4-11 (sorafenib IC50 0.002 M). In vitro activity of 234 
sorafenib against primary paediatric AML samples (4/6 FLT3-WT, 2/6 unknown FLT3 235 
status) was also demonstrated.50 Increased in vitro sensitivity of FLT3-mutated, primary 236 
paediatric AML samples has also been demonstrated for SU11657, a compound similar to 237 
sunitinib with anti-FLT3 activity51 Unlike sorafenib, sunitinib is no longer being evaluated as 238 
a FLT3 inhibitor in AML due to poor tolerability at doses required to inhibit FLT3.33 239 
 240 
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Several clinical trials of sorafenib in adult AML have been reported33, with a recent phase I/II 241 
study in combination with cytarabine and idarubicin demonstrating overall CR rates of 93% 242 
(14/15, plus 1 with CRp) in FLT3-ITD+ patients and 66% (24/36 plus 3 with CRp) in FLT3-243 
WT patients.52 In the phase II arm of the study, sorafenib was given at a dose of 400 mg 244 
twice daily for up to 28 days during induction and consolidation (both with concurrent 245 
cytarabine and idarubicin), then continued as maintenance therapy for up to one year.52  In 246 
contrast, a placebo-controlled, randomized phase II study of sorafenib combined with 247 
standard 7+3 induction chemotherapy and intermediate-dose cytarabine consolidation then 248 
continued for 1 year as maintenance in 197 older patients (> 60 years) failed to show any 249 
difference in CR rates, EFS, OS for FLT3-WT or FLT3-ITD+ patients, although the small 250 
number of FLT3-ITD+ patients (n = 28; 14.2%) may have limited the power of subset 251 
analysis. Despite being reportedly well tolerated, there was a trend towards slower leucocyte 252 
and platelet recovery in the sorafenib arm during the induction cycles.53 253 
 254 
Encouraging results from a paediatric phase I study of sorafenib in combination with 255 
cytarabine and clofarabine for children with relapsed/refractory acute leukaemia were 256 
recently published. Sorafenib was given as a single agent on days 1 to 7 and then 257 
concurrently with clofarabine (40 mg/m2, or 20 mg/m2 if the patient had HSCT within 6 258 
months or fungal infection within 1 month) and cytarabine (1 g/m2) on days 8 to 12. If 259 
tolerated, sorafenib alone was continued until day 28. Repeated courses of sorafenib, 260 
clofarabine and cytarabine, maintenance therapy with single-agent sorafenib, or 261 
transplantation were administered according to clinical judgment.27 Eleven of the 12 patients 262 
(aged 6-17 years) had AML, including 3 who had previously undergone allogeneic HSCT (2 263 
FLT3-ITD+, 1 FLT3-WT). Of these 11 AML patients, 5 were FLT3-ITD+ and all achieved 264 
morphological CR on day 22 (3 CR + 2 CRp) in combination with cytarabine and 265 
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clofarabine, including both patients who had previous allogeneic HSCT.27 Of the 6 FLT3-WT 266 
AML patients, 3 achieved morphological CR and one a PR. Of note, the initial seven-day 267 
course of single-agent sorafenib reduced bone marrow blast percentages in 10 patients 268 
(median 66%, range 9-95%), including all FLT3-ITD+ patients. Ten patients had PD studies 269 
performed (flow cytometric analysis of phosphorylated AKT, 4E-BP1 and S6RP), with 270 
decreases in percentage of positive cells and mean fluorescence intensity unrelated to FLT3-271 
mutational status.27 Six patients proceeded to HSCT.27 The most common toxicity associated 272 
with sorafenib was skin toxicity, with all 12 patients experiencing some degree of hand-foot 273 
skin reaction and/or rash. Skin toxicity was dose-limiting at 200 mg/m2 but not 150 mg/m2, 274 
which was the final recommended dose of sorafenib.27 The hand-foot skin (HFS) reaction to 275 
sorafenib is classically characterised by tender, scaling skin with erythematous halos on areas 276 
of pressure or skin creases which may blister and can progress to hyperkeratosis and impaired 277 
movement and function.54 Consensus guidelines for the management of sorafenib and 278 
sunitinib induced HFS reactions have been developed and include avoidance of skin trauma, 279 
liberal use of emollients and dose reduction/cessation of sorafenib.54 The high incidence of 280 
skin toxicity in this paediatric study compared to previous single agent adult trials was 281 
attributed the concurrent use of cytarabine and clofarabine, as well as the higher 282 
concentration of the active metabolite sorafenib N-oxide observed in the paediatric trial.27 283 
 284 
The current Children’s Oncology Group phase III trial (AAML1031, NCT01371981) is using 285 
a FLT3-ITD/FLT3-WT allelic ratio >0.4 (high-AR) to non-randomly stratify children with 286 
FLT3-ITD+ AML to receive sorafenib and HSCT in first remission, if an appropriate donor is 287 
available. Although the HSCT data for adults is inconclusive2, matched related donor 288 
allogeneic HSCT has been demonstrated to be of benefit for FLT3-ITD+ children with a high-289 
AR.31 The dismal prognosis for children with high-AR FLT3-ITD+ AML (3 year DFS/OS ≤ 290 
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20% ) clearly warrants novel treatment approaches however, the number of children with 291 
high-AR disease transplanted on the CCG-2941 and CCG-2961 trials was small (total FLT3-292 
ITD+ = 11; high-AR = 6), and all high-AR patients on the current COG AAML1031 trial will 293 
receive both sorafenib and allogeneic HSCT, so it may be difficult to determine the extent to 294 
which sorafenib further improves survival when compared to this historical control. 295 
 296 
Paediatric trials of other FLT3 inhibitors, including AC220, CEP-701 and PKC412, are 297 
currently in progress (Table I). An emerging issue with a number of FLT3 inhibitors, 298 
including midostaurin and the more selective compounds AC220 and sorafenib, is resistance 299 
mediated by secondary FLT3-TKD mutations.37-39,55,56 Given the biologically similar nature 300 
of FLT3-ITD+ AML in children and adults, similar resistance patterns could be expected 301 
although the relatively small number of children with FLT3-ITD+ AML may make this a rare 302 
occurrence. Finally, the benefit of “maintenance” FLT3 inhibition (e.g. post-HSCT) is yet to 303 
be proven, however it is plausible that such strategies with compounds like AC220 or 304 
sorafenib may promote acquired resistance, mediated by secondary FLT3-TKD mutations. 305 
Despite the compelling preclinical data supporting FLT3 inhibition as a therapeutic strategy 306 
in FLT3-mutated AML, until therapeutic benefit is proven from ongoing clinical trials in 307 
adults and children, up-front use of FLT3 inhibitors for childhood AML should be limited to 308 
clinical trials. However, for children with relapsed or refractory FLT3-ITD+ AML, limited 309 
therapeutic options (e.g. from anthracycline cardiotoxicity) and no access to a clinical trial, 310 
FLT3 inhibition could be considered to help achieve disease control, e.g., prior to HSCT or 311 
possibly even as a palliative strategy. 312 
 313 
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Immunotherapy 314 
Gemtuzumab ozogamicin 315 
Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to 316 
the cytotoxic compound N-acetyl-γ-calicheamicin dimethylhydrazine, has been extensively 317 
investigated in adults and children over the past decade. Therapeutic targeting of CD33 has a 318 
sound rationale in AML, since approximately 80% of AML cases express CD33.57 High 319 
CD33 expression in childhood AML is associated with adverse disease characteristics such as 320 
FLT3-ITD and independently predicts poor outcome.58 Initial experience with GO 321 
monotherapy in children with relapsed/refractory AML demonstrated response rates of 53% 322 
(8/15 patients), with 6 patients proceeding to HSCT.59 Subsequent trials, including GO 323 
combined with chemotherapy and HSCT have demonstrated its safety.60-63 Monotherapy 324 
studies and case reports of GO in relapsed/refractory childhood AML have resulted in a 325 
number clinically meaningful responses, whilst phase II studies in combination with 326 
chemotherapy have shown similar results to historical controls. The recently reported multi-327 
centre AML02 phase III trial included a randomization of GO (3 mg/m2) during induction II 328 
chemotherapy with cytarabine, daunorubicin and etoposide.64 Although the specific effects of 329 
GO versus no GO were not reported, GO in combination with ADE resulted in reductions in 330 
minimal residual disease (MRD) in 93% (27/29) of patients who had responded poorly to 331 
induction I, including all 8 patients with MRD > 25% after induction I. Of the 8 patients with 332 
MRD > 25%, half became MRD-negative with ADE+GO. Of the remaining 21 patients, who 333 
all had MRD > 1% after induction I, the ADE+GO combination reduced MRD in 19 (90%), 334 
with 9 patients becoming MRD-negative (43%).64 Paediatric phase III studies of GO in 335 
combination with conventional chemotherapy are ongoing. 336 
 337 
The potential for veno-occlusive disease (VOD) of the liver following GO has been of 338 
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concern in adult patients, particularly in those patients proceeding to HSCT within 3.5 339 
months of receiving 6 or 9 mg/m2 GO.65 The recently reported UK NCRI AML15 trial (1,113 340 
patients) administered a lower GO dose (3 mg/m2) in adults and failed to show an increased 341 
risk of hepatic toxicity, even when administered within 120 days of HSCT66 The successor 342 
trial, AML17 is randomizing adult patients to 3 vs. 6 mg/m2. In pediatric studies liver toxicity 343 
has been less of an issue, and GO seems better tolerated in children.67 344 
 345 
Other dosing strategies of GO have also been examined, including fractionated therapy, 346 
facilitating cumulative doses of up to 27 mg/m2 (ref 68-70). A phase I study in combination 347 
with busulfan and cyclophosphamide HSCT conditioning for 12 children with CD33+ AML 348 
(median age 3 years, range 1-17) failed to identify any GO-associated DLTs at 3.0, 4.5, 6.0 or 349 
7.5 mg/m2 and had no 100-day transplant-related mortality.61 350 
 351 
In June 2010 the United States Food and Drug Administration (FDA) withdrew marketing 352 
approval for GO, based on lack of benefit in relapsed/refractory AML and increased 353 
induction mortality in adults. It has been highlighted, however, that the increased induction 354 
mortality associated with GO was relative to an unusually low mortality in the control arm of 355 
one of the studies the FDA based their decision on.66 Furthermore, subsequent data from 356 
1,113 newly diagnosed patients treated on the UK NCRI AML15 trial have demonstrated a 357 
significant benefit of GO for patients with core binding factor (CBF) AML when given as a 358 
single dose of 3 g/m2 during courses one and three.66 The biological explanation for this is 359 
somewhat unclear, since responses to GO were not related to blast CD33 expression.66 360 
Interestingly, children with CBF AML on the NOPHO-AML 2004 trial accounted for 35% 361 
(N = 17) of relapses, independent of whether or not GO (5 mg/m2 x 2 doses) was given as 362 
post-consolidation therapy.71 Definitive results from larger paediatric trials of GO are 363 
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awaited. The recently reported French trial ALFA-0701 confirmed the survival advantage for 364 
adults with de novo AML and favourable cytogenetics, but also for those with intermediate-365 
risk cytogenetics. A notable feature of the ALFA-0701 study was the delivery of fractionated, 366 
higher cumulative doses of GO (3 g/m2 days 1, 4 and 7 during induction and in two 367 
consolidation cycles).70 On the basis of these adult studies with fractionated dosing, further 368 
evaluation of GO in children is planned. 369 
 370 
Stem cell targeting 371 
Bortezomib 372 
The proteasome inhibitor, bortezomib, was initially approved for use in multiple myeloma. 373 
Pre-clinical studies of proteasomal inhibition in combination with idarubicin in AML 374 
demonstrated down-regulation of NF-κB and preferential cell death in leukaemic stem cells 375 
but not normal haemopoietic stem cells (HSCs).72 A single-agent phase I study in children 376 
demonstrated acceptable toxicity, with a RP2D of 1.3 mg/m2 per dose when administered 377 
twice weekly for 2 weeks.73 Although NF-κB inhibition was observed in 2 of 5 evaluated 378 
patients, there were no objective clinical responses. Phase I studies of bortezomib (twice 379 
weekly for two weeks) in combination with chemotherapy in adult AML74 and paediatric 380 
ALL75 were also well tolerated, with predictable, chemotherapy-related toxicity. In the adult 381 
phase I combination study, nine patients were less than 60 years of age with relapsed AML, 382 
with the remaining 22 patients being over 60 years with untreated AML.74 Overall, 7/9 (78%) 383 
of relapsed patients and 15/22 (68%) untreated older patients achieved CR (including 3 384 
CRp).74 In addition to administering Sorafenib to children with high-AR FLT3-ITD+ AML, 385 
the current Children’s Oncology Group phase III trial (AAML1031, NCT01371981) is 386 
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randomising patients with de novo AML (including those with low-AR FLT3-ITD) to receive 387 
conventional chemotherapy with or without Bortezomib for all courses. 388 
 389 
Novel agents with promising data in adults 390 
Aurora kinase inhibition 391 
Aurora kinases are a family of serine/threonine kinases with critical roles in mitosis.76 Aurora 392 
A kinase plays a key role in centrosome maturation and mitotic spindle assembly whilst 393 
Aurora B kinase regulates the mitotic checkpoint, forms part of the chromosomal passenger 394 
complex (with inner centromere protein, Borealin and Survivin) and is required for final 395 
cytokinesis.76 Although therapeutic success in solid tumours has been limited, Aurora kinase 396 
inhibitors have shown encouraging responses in leukaemia, particularly AML and 397 
Philadelphia-positive leukaemias.77 A recent phase I/II trial of the selective Aurora B 398 
inhibitor, AZD1152 (barasertib) had an overall response rate of 25%.78 The toxicity profile, 399 
including mucositis and myelosuppression, was reported as being manageable in an older 400 
population. FLT3 kinase is a secondary target of AZD115279 and although the FLT3 status of 401 
patients on the trial was not reported, it is of interest that a number of responses occurred 402 
below the MTD and 55% of patients on the trial had cytogenetically normal AML (CN-403 
AML). Given the high incidence of FLT3 mutations in CN-AML, it is possible that the anti-404 
FLT3 activity of AZD1152 may have contributed to efficacy in patients with FLT3 405 
mutations. A phase II/III study of AZD1152, alone and in combination with low-dose 406 
cytarabine in older adults (> 60 years), is currently ongoing (NCT00952588). A recent 407 
preclinical study has demonstrated that paediatric AML cell lines are sensitive to Aurora B 408 
knockdown by shRNA and small molecule inhibition with AZD1152.80 One potential 409 
limitation of the AZD1152 compound is its delivery via a 7 day continuous IV infusion. 410 
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The selective Aurora A inhibitor MLN8237 (alisertib), has shown response rates of 17% in 411 
an adult phase II trial 81 and preclinical activity in paediatric leukaemia.82 Of note, a recent 412 
preclinical study in acute megakaryoblastic leukaemia (AMKL) demonstrated that Aurora A 413 
inhibition with MLN8237 could induce polyploidization in both a Down Syndrome (DS) 414 
AMKL cell line (CMK) and primary blasts from children with non-DS-AMKL. MLN8237 415 
also had in vivo activity against a non-DS-AMKL model.83 A paediatric phase II trial of 416 
MLN8237 in children with relapsed/refractory solid tumours and leukaemia is currently 417 
ongoing (NCT01154816, COG-ADVL0921). Similarly, the Aurora kinase inhibitor AT9283, 418 
which also has potent activity against ABL, JAK2 and FLT3 kinases, has shown encouraging 419 
responses in adult leukaemia trials and is currently being assessed in a paediatric phase I 420 
study (EudraCT No. 2009-016952-36; NCT01431664). 421 
 422 
MEK inhibition 423 
Mutations of N- and K-RAS in AML are examples of class I mutations, conferring a 424 
proliferative/survival stimulus.84 A recent comprehensive pre-clinical predictive biomarker 425 
analysis of 218 solid tumor and 81 haematological cancer cell lines revealed AML and CML 426 
cell lines as being particularly sensitive to the MEK inhibitor, GSK1120212.85 Amongst solid 427 
tumour cell lines, RAF/RAS mutations were predictive of sensitivity.85 In a panel of 12 AML 428 
cell lines, single-nanomolar IC50’s were reported for all 6 RAS-mutant (N- or K-RAS) cell 429 
lines, as well as 2 RAS-wt cell lines. The paediatric cell line Kasumi-1 (RAS-wt) was 430 
resistant, although other paediatric cell lines, THP-1 (N-RAS mutant) and MV4-11 (FLT3-431 
ITD+, RAS-wt), were sensitive.85 A phase I trial of GSK1120212 was reported at the 2010 432 
ASH meeting, with 12 of 14 patients treated having AML (including 2 transformed from 433 
MDS).86 Preliminary anti-leukaemic activity was reported, with one patient achieving CR. A 434 
phase I/II study of GSK1120212 in AML is ongoing (NCT00920140). 435 
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 436 
Aminopeptidase inhibition 437 
Aminopeptidases play a key role in removing amino acids from cellular peptides, a process 438 
required for protein regulation and recycling. Aminopeptidase inhibition depletes intracellular 439 
amino acids required for new protein synthesis.87 AML cells have been shown to be sensitive 440 
to aminopeptidase inhibition, undergoing apoptosis, whilst normal bone marrow cells are less 441 
susceptible.88 The aminopeptidase inhibitor Tosedostat has shown promising activity in phase 442 
I/II trials of older adults with predominantly relapsed/refractory AML, with single-agent 443 
response rates of up to 27%.89,90 Tosedostat appears well tolerated with thrombocytopaenia 444 
being the most common adverse event reported. 445 
 446 
c-KIT inhibition 447 
Activating c-KIT mutations are common in paediatric and adult AML, particularly in CBF 448 
AML (incidence 21-54.5% with inv(16) and 17-46.8%% with t(8;21)).91-95 Although c-KIT 449 
mutations confer an increased risk of relapse in adults with CBF AML93, this does not appear 450 
to be the case in children.94,95 Murine models have demonstrated c-KIT mutations cooperate 451 
with AML1-ETO to cause aggressive AML in vivo, but are responsive to c-KIT inhibition 452 
with dasatinib.96 Dasatanib has also been shown to have single-agent activity against the 453 
t(8;21) paediatric cell line, Kasumi-1, which also harbours an N822K point mutation in the 454 
activation loop of c-KIT.97,98 Results of several ongoing clinical trials in AML, particularly 455 
those enriched with CBF patients, are eagerly awaited. 456 
 457 
CXCR4 antagonism 458 
The critical role of the bone marrow micro-environment, or “niche” in regulating normal and 459 
malignant haematopoiesis is becoming increasingly recognised. The CXCR4 antagonist, 460 
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plerixafor, has demonstrated efficacy in the mobilization of normal HSCs from the marrow 461 
for use in autologous transplantation in non-Hodgkin lymphoma and multiple myeloma.99,100  462 
Plerixafor has also been demonstrated to be a feasible and effective second-line strategy in 463 
mobilizing HSCs in children.101,102 Based on pre-clinical data demonstrating AML blasts 464 
could be mobilized into the peripheral blood, a recent phase I/II study demonstrated the 465 
feasibility of combining plerixafor with cytotoxic chemotherapy in adults with 466 
relapsed/refractory AML. When used in combination with mitoxantrone, etoposide and 467 
cytarabine, plerixafor increased mobilization of AML blasts into the peripheral circulation.103 468 
Overall CR rates of 46% were achieved and no dose-limiting toxicities were observed. 469 
 470 
Epigenetic therapies 471 
Genes regulating DNA methylation and demethylation such as DNMT3A, IDH1/2 and TET2 472 
are frequently mutated in adult AML and have prognostic significance.104-107 Consequently, 473 
targeting epigenetic processes has become an attractive therapeutic strategy in adult AML. 474 
The DNA methyltransferase inhibitors decitabine and azacitidine are currently being 475 
evaluated in clinical trials of adults with AML and paediatric evaluation programs are being 476 
designed. A recent analysis of 46 patients treated on two trials of decitabine has shown an 477 
improved response rate in patients with DNMT3A mutations compared to those with wild-478 
type DNMT3A (CR rate 75% (6/8) vs. 34% (13/38) respectively, P=0.05).108 Studies of 479 
azacitidine alone and in sequential combination with lenalidomide have shown responses of 480 
approximately 50% in older adults with newly-diagnosed AML compared to those with 481 
relapsed disease.109,110 482 
 483 
Another focus of epigenetic therapy has been histone deacetylase (HDAC) inhibition with 484 
compounds such as valproic acid, vorinostat and panabinostat. Widely used as an anti-485 
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convulsant, valproic acid was first demonstrated to inhibit HDAC and cause partial 486 
differentiation of the paediatric AML cell line Kasumi-1 over a decade ago.111 Preclinical 487 
studies, including paediatric models, have also demonstrated single cytotoxic synergy with 488 
cytarabine and clofarabine.112,113 Clinical responses to valproic acid alone or in combination 489 
with cytarabine in adults with AML however, have been variable.114-116 It should be noted 490 
that when combined with decitabine, valproic acid has been associated with 491 
encephalopathy.117  492 
 493 
Although a single-agent randomised phase II trial of vorinostat in adults with relapsed or 494 
high-risk untreated AML showed only minimal responses (1 CR from 37 patients)118 a recent 495 
phase II trial of vorinostat in combination with idarubicin and cytarabine (IA) in patients with 496 
AML and no CBF abnormalities resulted in an EFS of 47 weeks (range, 3 to 134 weeks) and 497 
a CR rate of 76%. Although not randomised, these responses compared favourably to 498 
historical data, the combination was reported as not excessively toxic compared to IA alone 499 
and all 11 FLT3-ITD+ patients responded (10 CR, 1 CRp).119 As discussed above, the relative 500 
rarity of mutations in genes regulating DNA methylation in childhood AML may limit the 501 
broader applicability of these agents for children, particularly if responses are confirmed to be 502 
associated with mutational status.  503 
 504 
Although adult clinical trials have only recently been initiated, it is worth noting one potential 505 
epigenetic therapy that may be of significant importance to childhood leukemias with MLL 506 
gene rearrangements, given their relatively high incidence (AML 18%, ALL 8.3%).4 The 507 
histone H3 methyltransferase, DOT1L, plays a key role in MLL-fusion mediated 508 
leukemogenesis (reviewed in Ref 120). A small molecule inhibitor of DOT1L, EPZ004777, 509 
was recently shown to have in vivo preclinical efficacy against MLL-rearranged 510 
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leukemia.121,122 A phase I trial of an optimized compound, EPZ-5676, opened in September 511 
2012 for adults patients with advanced hematological malignancies, including MLL-512 
rearranged AML and ALL (NCT01684150). 513 
 514 
Finding and Hitting the Right Target in AML: Predictive and 515 
Pharmacodynamic Biomarkers 516 
Of critical importance for the rational and efficient development of targeted agents in cancer 517 
and leukaemia is the use of validated predictive and PD biomarkers. Predictive biomarkers 518 
are those that identify which patients are most likely to derive benefit from a given targeted 519 
agent, whilst PD biomarkers are needed to verify whether or not the desired molecular target 520 
is being modulated, and establish how target modulation relates to dose, toxicity and 521 
response. This information, together with careful examination of any resistance mechanisms 522 
or treatment failures, not only decreases the attrition rate of targeted therapeutics, but also 523 
improves the ongoing pre-clinical development of new agents. 524 
 525 
FLT3 inhibitors provide arguably the best example of how robust predictive and PD 526 
biomarkers have been successfully applied in AML. It is well established that patients 527 
without activating mutations of FLT3 are less likely to benefit from FLT3 inhibition.33 Even 528 
with potent, second generation FLT3 inhibitors such as AC220, response rates in FLT3-WT 529 
patients are lower than in FLT3-ITD+ patients (34 vs. 44%).123 FLT3 mutational status 530 
therefore serves as a robust predictive biomarker for personalized AML therapy. 531 
Furthermore, results from trials of CEP-701 clearly demonstrate the importance of combining 532 
a predictive biomarker with a robust PD assay, since adequate FLT3 inhibition correlates 533 
with outcome for FLT3-mutated patients treated with CEP-701.45,47 An important PD assay 534 
developed for FLT3 inhibitors is the PIA assay.42 This assay involves incubation of a FLT3-535 
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ITD+ cell line in the plasma of patients treated with FLT3 inhibitors. The degree of FLT3 536 
inhibition seen ex vivo for a patient at a given time-point during or after therapy is normalized 537 
to the amount of FLT3 phosphorylation observed when cells are incubated with that patient’s 538 
pre-treatment plasma. FLT3 ligand (FL) levels and protein binding can impact on the efficacy 539 
of FLT3 inhibition.46 The PIA assay is therefore superior to simply calculating the free drug 540 
concentration, since the plasma sample used to treat the cell line ex vivo contains not only 541 
free drug, but also the patient’s actual FL and plasma proteins at that time-point. Using the 542 
PIA assay, it has recently been demonstrated that when adequate FLT3 inhibition is achieved 543 
in combination with chemotherapy, relapse rates are lower and overall survival can be 544 
improved.47  545 
 546 
The relatively small circulating blood volume and need for general anaesthetic when 547 
performing bone marrow aspiration can limit the number and nature of PD assays undertaken 548 
in paediatric leukaemia trials. Assays such as the PIA assay have been successfully adapted 549 
for use in children, such that smaller blood volumes are required, permitting use in phase I 550 
paediatric trials.124 Furthermore, the PIA assay has been successfully adapted and validated 551 
for therapeutic targets other than FLT3, with inhibition of phosphorylated histone H3 being 552 
used as a PD biomarker of Aurora kinase inhibition in a paediatric trial of AT9283 (EudraCT 553 
No. 2009-016952-36, NCT01431664).124 554 
 555 
Future Directions and Trial Design 556 
Although the prognosis for children with AML has improved over recent decades, such 557 
improvements are largely attributable to more intensive use of cytotoxic chemotherapy and 558 
better supportive care.6 Although a number of novel therapeutic agents have been recently 559 
developed and show promising efficacy in adult AML, significant issues still exist for 560 
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executing early phase clinical trials of such drugs in children. Often, patients may progress 561 
rapidly between screening and commencing a novel therapy, by which time they may become 562 
ineligible with poor performance status or complicating conditions such as uncontrolled, 563 
invasive infection. Furthermore, patients relapsing soon after allogeneic HSCT may have 564 
poor organ function deeming them ineligible. One possible solution is to treat patients with 565 
primary refractory or first-relapsed AML with targeted novel agents in a “window” period 566 
prior to allogeneic HSCT. Several factors need to be considered for this approach though, 567 
including the likelihood of achieving CR with second or third line chemotherapy, the 568 
potential of the novel agent causing organ toxicity which could compromise the success of 569 
subsequent HSCT and the time required to screen, enroll and treat patients with the novel 570 
agent prior to HSCT. 571 
 572 
Accelerating drug development for childhood AML will rely heavily on effective 573 
international collaboration, particularly if enrolment on targeted therapeutic trials is to be 574 
restricted to the relatively small number of patients with predictive biomarkers of response. 575 
Groups such as the Innovative Therapies for Children with Cancer (ITCC) European 576 
Consortium and the Therapeutic Advances in Childhood Leukaemia and Lymphoma (TACL) 577 
consortium have an existing focus on early-phase trials of novel agents for childhood 578 
leukaemia. Although legislative, regulatory and pharmaceutical supply barriers prevent the 579 
enrolment of children from outside Europe or North America on certain trials, attempts to 580 
facilitate truly international early-phase studies are ongoing. Novel approaches to early-phase 581 
trial design are also critical in accelerating drug development, particularly in children. 582 
Important strategies include phase I trials with expansion cohorts at the RP2D enrolling 583 
patients with predictive biomarkers, and adaptive randomised trials incorporating a number of 584 
new agents with the aim of “picking-the-winner” or “dropping-the-loser”.125 Such approaches 585 
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hold promise of reducing the number of large phase III trials needed and improving the 586 
likelihood of beneficial treatments being identified for malignancies like AML with 587 
increasingly heterogeneous biology. The important question of how much can be extrapolated 588 
from adult biology and trial data remains difficult to answer, hence defining the minimum 589 
dataset in children is an ongoing challenge. 590 
 591 
Although significant challenges remain for novel drug development in paediatric oncology, 592 
particularly AML, the encouraging results of initial paediatric trials of therapies such as 593 
clofarabine and sorafenib, together with the large number of new agents in the pipeline is 594 
encouraging. Although survival rates in childhood AML are significantly better than adults 595 
with the disease, outcomes for children with AML are dramatically inferior compared with 596 
paediatric ALL.4 Improving outcomes in AML with cytotoxic chemotherapy alone is highly 597 
unlikely, given the current intensity of conventional therapy. Continued efforts to find 598 
effective novel therapies are therefore of critical importance if survival is to be improved and 599 
long-term morbidity reduced. 600 
  601 
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Table I. Current clinical trials of new agents in childhood AML 1153 
Class Phase Ages 
(years) 
Target / Comments Trial number 
Nucleoside analogues 
Clofarabine I 0-28 In combination with thiotepa, topotecan 
and Vinorelbine 
NCT00462787 
MSKCC-07012 
Clofarabine II 1-30 In combination with cytarabine NCT00372619 
COG-AAML0523 
Clofarabine I-II 0-30 In combination with cytarabine and TBI 
as conditioning for allo-HSCT 
NCT00529360 
Clofarabine I 0-18 In combination with cytarabine and 
liposomal daunorubicin 
Dutch Trial 
Registry 1880 
 
FLT3 inhibitors 
Lestaurtinib 
(CEP-701) 
III 0-60 FLT3-mutated patients randomised to 
CEP-701 or placebo after induction I; 
small numbers of paediatric patients. 
ISRCTN55675535 
Midostaurin 
(PKC412) 
I-II 3 mo - 18 FLT3-mutated AML; MLL-rearranged 
ALL 
NCT00866281 
EudraCT No. 
2008-006931-11 
Sorafenib III 0-29 For FLT3-ITD+ patients with high-allelic 
ratio (> 0.4) 
NCT01371981 
COG-AAML1031 
Quizartinib 
(AC220) 
I 1mo - 21 Combination with cytarabine and 
etoposide 
NCT01411267 
T2009-004 
Aurora kinase inhibitors 
AT9283 I 6 mo -18 IV, multi-kinase inhibitor (Aurora, ABL, 
FLT3, JAK2) 
EudraCT No. 
2009-016952-36 
NCT01431664 
MLN8237 II 1-21 Selective Aurora A inhibitor NCT01154816 
COG-ADVL0921 
Monoclonal antibodies 
Gemtuzumab 
ozogamicin 
III 0-29 Anti-CD33 mAb conjugated to 
cytotoxic calicheamicin 
NCT01407757 
COG-AAML0531* 
Brentuximab 
vedotin 
II ≥ 6 Anti-CD30 mAb conjugated to anti-
microtubule compound MMAE 
NCT01461538 
Proteasome inhibitors 
Bortezomib III 0-29 Bortezomib in combination with 
standard chemotherapy (ADE x 2, AE, 
A/Mitox) 
NCT01371981 
COG-AAML1031 
Other novel agents 
Panabinostat I 8-21 HDAC inhibitor NCT01321346 
T2009-012 
INCB18424 I 1-21 JAK1/2 inhibitor NCT01164163 
COG-ADVL1011 
MK2206 I 1-21 Akt inhibitor NCT01231919 
COG-ADVL1013 
Obatoclax 
mesylate 
I 0-21 BCL-2 inhibitor, in combination with 
vincristine, doxorubicin and 
dexrazoxane 
NCT00933985 
COG-ADVL0816 
Decitabine II 1-16 Hypomethylating agent as epigenetic 
priming for induction chemotherapy with 
ADE 
NCT01177540 
Fenretinide I 0-21 Cytotoxic retinoid NCT01187810 
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Abbreviations: TBI, total body irradiation; allo-HSCT, allogeneic haematopoietic stem cell 1155 
transplantation; AML, acute myeloid leukaemia; ALL, acute lymphoblastic leukaemia; MLL, 1156 
mixed lineage leukaemia gene; mo, months; mAb, monoclonal antibody; MMAE, 1157 
monomethyl auristatin E; HDAC, histone deacetylase; ADE, cytarabine, daunorubicin, 1158 
etoposide; AE, cytarabine etoposide; A/Mitox, cytarabine and mitoxantrone; *ongoing, but 1159 
closed to recruitment. 1160 
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